hypericin has been researched along with HIV Coinfection in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypericin has potent activity against HIV and other viruses, is compatible with anticoagulants used to store blood, and does not affect blood chemistry when stored for 21 days." | 3.69 | Hypericin: an answer for safer blood? ( Kuhn, D, 1995) |
| "Severe cutaneous phototoxicity was observed in 11 of 23 (48% [95% CI, 27% to 69%]) evaluable patients, and dose escalation could not be completed." | 2.69 | Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. ( Crumpacker, C; Forcht, J; Gulick, RM; Holden-Wiltse, J; Hussey, S; Liebes, L; McAuliffe, V; Meehan, P; Stein, DS; Valentine, FT, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gulick, RM | 1 |
| McAuliffe, V | 1 |
| Holden-Wiltse, J | 1 |
| Crumpacker, C | 1 |
| Liebes, L | 1 |
| Stein, DS | 1 |
| Meehan, P | 1 |
| Hussey, S | 1 |
| Forcht, J | 1 |
| Valentine, FT | 1 |
| Kuhn, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes[NCT00000645] | Phase 1 | 32 participants | Interventional | Completed | |||
| A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects[NCT00000792] | Phase 1 | 24 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hypericin and HIV Coinfection
| Article | Year |
|---|---|
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.
Topics: Administration, Oral; Adult; Anthracenes; Anti-HIV Agents; CD4 Lymphocyte Count; Dermatitis, Phototo | 1999 |
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.
Topics: Administration, Oral; Adult; Anthracenes; Anti-HIV Agents; CD4 Lymphocyte Count; Dermatitis, Phototo | 1999 |
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.
Topics: Administration, Oral; Adult; Anthracenes; Anti-HIV Agents; CD4 Lymphocyte Count; Dermatitis, Phototo | 1999 |
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.
Topics: Administration, Oral; Adult; Anthracenes; Anti-HIV Agents; CD4 Lymphocyte Count; Dermatitis, Phototo | 1999 |
1 other study available for hypericin and HIV Coinfection
| Article | Year |
|---|---|
Hypericin: an answer for safer blood?
Topics: Anthracenes; Antiviral Agents; Blood Preservation; Blood-Borne Pathogens; Clinical Trials as Topic; | 1995 |